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Background: Uraemia is associated with a highly increased risk of cardiovascular disease. Mannose-binding lectin
(MBL) has been shown to be involved in cardiovascular pathophysiology and a protective effect of MBL is suggested.
The purpose of the present study was to evaluate a potential impact of MBL on vascular parameters in uraemic
patients.
Methods: A cohort of 98 patients with end stage renal disease (ESRD) awaiting kidney transplantation had pulse wave
velocity (PWV) and augmentation index (AIX) examined by tonometry and endothelial dependent flow-mediated
(FMD) and endothelial independent nitroglycerin-induced (NID) dilatory capacities of the brachial artery measured by
ultrasound. An oral glucose tolerance test (OGTT) was performed and serum levels of MBL were measured using
Luminex xMAP bead array technology.
Results: The cohort was divided in two groups according to MBL-concentration below or above the median
concentration. These groups were comparable regarding age, BMI, and duration of ESRD. PWV was significantly
lower in the group with high MBL levels compared to the group with low MBL levels and trends toward better AIX
and higher insulin sensitivity (ISI) was also seen in the group with high MBL levels. No difference was seen in FMD
and NID.
Conclusions: High levels of MBL are associated with lower PWV and the use of antihypertensive drugs in a cohort
of patients with ESRD awaiting kidney transplantation suggesting a beneficial role of high levels of MBL on arterial
stiffness in uraemia.
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lectinBackground
Uraemia is associated with a highly increased risk of cardio-
vascular disease. Vascular function in uraemic patients is
severely damaged by a number of factors including in-
creased phosphate, hypertension and increased calcification
of large arteries. Stiffness of elastic large arteries as mea-
sured by pulse wave velocity are associated with increased
mortality [1,2]. Hypertension and age seems to be especially
important for the development of arterial stiffness in non-* Correspondence: mads.hornum@regionh.dk
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unless otherwise stated.diabetic uraemic patients [3]. Other factors like inflamma-
tion, infections and hyperlipidaemia damage the endothelial
function as measured by flow mediated vasodilatation in
the brachial artery [4,5]. Genetically determined variation in
MBL- serum concentration has been shown to affect the
clinical course of cardiovascular disease, and an impairment
of endothelial function caused by low MBL concentrations
has been described in childhood infection [6]. Potential ef-
fects of MBL concentrations on arterial stiffness are not
well described and especially the potential influence of
MBL in the deterioration of arterial and endothelial func-
tion in uraemia needs further investigation.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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impact of MBL on vascular parameters in uraemic patients.Methods
This is a prospective, observational cohort study including
98 patients with a scheduled living donor kidney trans-
plantation (n = 48) or deceased donor transplantation on
the waiting list for transplantation (n = 50) in the period
between January 2006 and March 2008 at the two trans-
plantation centres in Copenhagen (Copenhagen University
Hospital, Rigshospitalet and Herlev Hospital (Tx-group)).
To be included the patients had to be between 18 to 65
years of age with no more than one previous kidney
transplantation.
The Scientific-Ethical Committee of the Capital Region
of Denmark (# KF 01279825) and The Data Protection
Agency (#2006-41-5640) approved the study. All partici-
pants gave their informed written consent.Study procedure
All participants were examined before kidney transplant-
ation. The majority of the patients were anuric and the
few with remaining diuresis all had an estimated baseline
creatinine clearance below 15 ml/min. The examinations
were performed after an overnight fast including coffee,
tobacco, and exercise abstinence for 10 hours. Antihyper-
tensive medication was allowed in the morning. The
examiners were blinded regarding the actual clinical and
metabolic status of the patient at the time of examination
and all clinical information was analyzed and described
after data collection was completed. Data regarding dur-
ation of smoking history, ESRD, antihypertensive treat-
ment were obtained by interview and from the medical
record. Weight and height were measured.
Hemodialysis patients were examined between days of
hemodialysis. Peritoneal dialysis patients had the periton-
eal fluid (PF) drained in the morning at 6 a.m. The OGTT
was performed more than 12 hours after last instillation of
PF and more than 4 hours after draining the PF. After 10
minutes in the supine resting position blood pressure was
measured in the arm opposite to a fistula or dialysis cath-
eter. Mean arterial blood pressure (MAP) was given as
mean of three measurements. Fasting blood samples were
drawn in an antecubital vein from the same arm for the
determination of plasma (p)-glucose (PG), p-CRP and
p-homocystein. PG concentrations were analysed by the
glucose-hexokinase method (Gluco-quant®, Roche Diag-
nostics GmbH, D-68298 Mannheim, Germany) and
p-insulin were measured using enzyme-linked immuno-
sorbent assay kits (Elecsys, Roche Diagnostics GmbH, D-
68298 Mannheim, Germany). All assays were automated
and performed on a Cobas Fara robot (Roche Diagnostics
GmbH, Mannheim, Germany).Measurement of serum MBL
Serum MBL concentrations were measured using an anti-
MBL monoclonal antibody double sandwich technique
based on the Luminex xMAP bead array technology as pre-
viously described [7]. In healthy subjects the median day-
to-day variability in MBL concentrations expressed as CV
was 6%. The lower detection level was 5 μg/L and intra-
and interassay CVs were below 5 and 10%, respectively.
MBL2 genotypes
Blood collected in 10 ml EDTA containing vacutainers was
used for DNA extraction. Anticoagulated blood was frozen
at −80°C before DNA processing. MBL2 single nucleotide
polymorphisms (SNPs) in form of the structural variants
named B (codon 54, rs1800450, C (codon 57, rs1800451,
and D (codon 52, rs5030737) were typed by PCR using se-
quence specific priming (PCR-SSP) as previously described
[8]. The normal allele is designated “A”. All three structural
variant alleles (B, C, and D) have a considerable effect on
MBL concentrations and to avoid small groups, the three
alleles were grouped in one category called allele “O” for
statistical analyses.
Standard laboratory methods were applied for the ana-
lysis of the other samples.
Pulse wave analysis and velocity
PWV and AIX of the carotid-femoral pulse wave was re-
corded sequentially at the carotid and femoral artery
using applanation tonometry (SphygmoCor®; AtCor
Medical, Sydney, NSW, Australia) performed by the
same observer (MH) as previously described in detail
[3]. The reproducibility of AIX and PWV for two repeat
scans on two different days in ten uraemic patients from
the present study was analysed using the Bland Altman
method. The mean ± SD intra-observer difference was
0.1 ± 0.7 m/s for PWV, 1.7 ± 5.5 % for AIX, which is in
accordance with other groups [4,9].
Flow mediated vasodilatation (FMD) and
nitroglycerin-induced dilatation (NID)
An Acuson 128XP/10™ ultrasound system with extended
frequency-imaging option and a 7-MHz linear transducer
was used to measure the brachial artery dilatory responses
to increased flow (FMD) and to nitroglycerin (NID) based
on previous published methodology by our group and
others [4,9,10].
External ultrasound measurements of FMD and NID
have previously been shown to provide accurate and re-
producible results. Coefficients of variation of the diam-
eter changes expressed as diameter in percentage of the
baseline scan diameter (100%) in the present study was
4.4 and 4.1% for FMD and NID for eight scans of the same
subject from the present study population (within patient
variability) performed on separate days within a period of
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ports [9,11].
Evaluation of glucose tolerance
A 75-gram OGTT was performed according to the WHO
criteria [12] and an insulin sensitivity index (ISI) was calcu-
lated as previously described in details [13].
Antihypertensive treatment
Antihypertensive treatment mainly included beta-blockade,
calcium channel blockade, angiotensin-II-blockade and
diuretics.
Statistics
Data analyses were performed using Statistical Analysis
Software (SAS®) version 9.1. Unless specified otherwise,
continuous data is described as mean ± standard deviation
(SD) or median and range for normal and skewed distribu-
tions, respectively. The Shapiro-Wilk W test and a normal
plot were used to judge normality. Group comparisons of
continuous data were performed using unpaired t-test test
for normally distributed data or non-parametric Wilcoxon
Rank Sum Test or Kruskal-Wallis non-parametric one way
analysis of variance test. Chi square or Fisher’s exact tests
were used for group comparisons between categorical data
where appropriate. A p value of <0.05 was used to deter-
mine significance.
Results
The cohort was divided in two groups according to MBL
concentration below or above the median concentration.
These groups were comparable regarding age, hyperten-
sion, glycemic status, BMI, and duration of ESRD.
Univariate analysis showed no association between the
MBL level and PWV, ISI, FMD, NID or augmentation
index in the whole group but the variance analysis be-
tween the two groups demonstrated that PWV was sig-
nificantly lower in the group with high MBL levels
compared to the group with low MBL levels (Table 1,
p = 0.03) and trends toward better AIX and higher ISI
was also seen in the group with high MBL levels. No dif-
ference was seen in FMD or NID. Systolic and diastolic
blood pressure was similar between groups, however the
use of antihypertensive drugs were significantly higher in
the group with the lowest PWV and highest MBL
(Table 1).
Data on myocardial infarction, stroke and smoking were
collected and there was no difference between the groups
(Table 1).
The variance analysis was also performed for the whole
group with factors known to influence PWV, describing
65% of the variance and as expected age, hypertension,
glucose intolerance, insulin resistance and homocystein
was significantly associated with PWV, but MBL levels justdid not reach statistical significance in this analysis
(Table 2).
Distribution of the genetic MBL2-variants differed as re-
sult of the stratification according to MBL below or above
the median. The normal A/A genotype dominated in the
group above the median (44 vs. 5), whereas patients hetero-
zygous for MBL2 variants (A/O) haplotype were predomin-
ant in the group below the median (41 vs. 5). Those
heterozygous for the structural variants, the O/O genotype,
were found only in the group below the median (6 vs. 0),
(Table 3). The difference in MBL concentrations between
the MBL2 variants is shown in Figure 1.
The distribution of haemodialysis or peritoneal dialy-
sis, and the use of an arterio-venous fistulae or a per-
manently haemodialysis catheter, was determined in the
cohort, and there were no statistical difference in PWV,
ISI, FMD, NID or augmentation index between the
groups divided by MBL levels.
Discussion
In a cohort of patients with ESRD awaiting kidney trans-
plantation we found that high levels of MBL and increased
use of antihypertensive drugs were associated with lower
PWV. There may be a beneficial role of high levels of
MBL on arterial stiffness in uraemia which was independ-
ent of BMI, length of uraemia and age. Previously Cheung
et al. [14] demonstrated that the MBL genotype influenced
arterial stiffness in Chinese children with Kawasaki Dis-
ease. The children with low level MBL expression IL/LL-
genotypes without coronary complications had faster
PWV/stiffer peripheral conduit arteries than children with
high level MBL expression HL- genotypes indicating that
a high level of MBL had a protective effect on arterial
function. In a study of healthy Danish blood donors aged
18–65 years, the median value of MBL was 967.5 ug/L (8–
4693 ug/L) [7]. Arterial stiffness estimated by PWV [15]
reflects damage of the elastic tissue of aorta [15,16] and is
associated with increased mortality in ESRD-patients
[17,18]. In a cohort of 66 uraemic patients we previously
reported that age and mean arterial pressure but not pre-
diabetes were independently associated with increased
PWV [3] and an age and BMI matched healthy control
group previously studied by our group had significant
lower blood pressure and a better augmentation index,
FMD and NID compared to uraemic patients on the wait-
ing list for Tx [19]. In the present cohort divided by the
median level of MBL there was no difference in age, fast-
ing glucose, 2-hour blood glucose, ISI or blood pressure
between the groups, however more antihypertensive drugs
were used in the group with high MBL levels and the low-
est PWV, indicating that the role of MBL in uraemia
seems independently of traditional risk factors for an in-
creased PWV. Although not significant, both augmenta-
tion index and ISI index was more favourable in the high
Table 1 Comparison of clinical and demographic data between patients with a MBL level above or below the median
MBL < 722 ug/L MBL >722 ug/L
N = 49 N = 49
Age (years) 45.3 ± 13.0 41.6 ± 12.4
ESRD (months) 29 (0–168) 33 (0–120)
Dialysis status:
Haemodialysis (N) 34 32
Peritoneal dialysis (N) 13 13
Pre-dialysis (N) 2 4
Haemodialysis, venous access: Arterio-venous fistulae/permanently haemodialysis catheter (N) 15/19 15/17
Tx status (living donor/deceased donor) 22/27 26/23
Myocardial infarction (N) 2 2
Smoking (N) 15 14
Stroke (N) 3 2
Diabetes (N) 3 5
Impaired fasting glucose (N) 1 2
Impaired glucose tolerance (N) 21 13
Normal glucose tolerance (N) 24 29
Fasting plasma glucose (mmol/L) 5.0 ± 0.4 5.1 ± 0.5
OGTT 120min(mmol/L) 8.0 ± 2.1 7.7 ± 2.1
ISI (index) 7.4 ± 4.1 7.9 ± 4.9
BMI (kg/m2) 24.2 ± 3.8 24.5 ± 3.6
PWV (m/s) 8.2 (5.6-15.8) 6.8 (5.2-16.4)*
AIX (%) 27 (−10;56) 20 (−7;50)
FMD (%) 3.8 (−8.3;19.2) 3.5 (−6.8;19.1)
NID (%) 10.5 (2.9;27.1) 11.5 (2.0;27.2)
Systolic blood pressure (mmHg) 143 ± 25 140 ± 19
Diastolic blood pressure (mmHg) 85 ± 12 84 ± 13
Number of antihypertensive drugs 2 (0–5) 3 (0–6)*
P-C-reactive protein (mg/L) 2 (1–40) 2 (1–21)
P-Homocystein (umol/L) 21 (11–62) 22 (12–150)
P-PTH (pmol/L) 21 (2–100) 20 (4–156)
P-ionized calcium (mmol/L) 1.19 ± 0.09 1.21 ± 0.09
P-phosphate (mmol/L) 1.8 ± 0.4 2.0 ± 0.6
Data are presented as mean (SD) or median and range.
MBL: Mannose Binding Lectin, ESRD: end-stage renal disease,
Tx: transplantation, BMI: body mass index, PTH: parathyroidea hormone,
OGTT: oral glucose tolerance index, ISI: insulin sensitivity index.
PWV: pulse wave velocity,
AIX: Augmentation Index, FMD: flow mediated vasodilatation,
NID: nitroglycerin independent dilatation,
*P < 0.05.
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this group, and a more powerful study including more pa-
tients might confirm this association.
The duration of ESRD in the groups divided by the
median MBL was not significantly different, an import-
ant point, since duration of haemodialysis increases
MBL levels as demonstrated by Satomura et al. [20].Apart from influencing arterial stiffness, MBL deficiency
is also known to be associated with severe atherosclerosis
[21] and doubles the risk for myocardial infarction (MI) in
young relatively healthy Caucasians [22], and leads to car-
diovascular events in type 2 diabetic South Asians [23].
Furthermore, MBL deficiency has been shown to be un-
favourable in type 2 diabetic Caucasians with MI [24].
Table 2 Results of an ANOVA of factors obtained at baseline in 98 ESRD patients awaiting kidney transplantation the
model describes 65% of the variance in PWV (P < 0.0001)
Parameter Effect on PWV(m/s) 95% confidence intervals P-value
Intercept −0.14 −3.66; 3.38 0.94
Age (years) 0.12 0.08; 0.16 <0.0001
BP >130/80 mmHg 1.76 0.81; 2.72 0.0005
BP < 130/80 mmHg (reference group) 0
Number of antihypertensives (n) −0.08 −0.45;0.29 0.65
ISI (index) 0.21 0.07; 0.36 0.0043
OGTT120min 0.33 0.09; 0.56 0.0067
Homocystein (umol/L) 0.03 0.01; 0.05 0.01
MBL Genotype A/A 1.23 −1.21; 3.66 0.32
MBL Genotype A/O 0.18 −1.85; 2.21 0.86
MBL Genotype O/O (reference group) 0
LogMBL −0.88 −1.85; 0.10 0.0764
Female sex 0.31 −0.81; 1.42 0.58
Male sex (reference group) 0
ESRD (months) −0.01 −0.03; 0.01 0.22
Augmentation Index −0.01 −0.05; 0.03 0.51
CRP (mg/L) −0.04 −0.11; 0.04 0.32
Kruskal-Wallis one way of variance analysis of the effect on pulse wave velocity (PWV) using factors obtained at baseline. BP: blood pressure; ISI: insulin sensitivity
index; OGTT: oral glucose tolerance test; MBL: mannose-binding lectin; ESRD: end-stage renal disease; CRP: C-reactive protein.
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with normal renal function, they demonstrated that espe-
cially the combination of genotype O/O and impaired glu-
cose metabolism was a hazardous combination with
impact on cardiovascular events. In haemodialysis patients
low MBL levels has been found to be associated with in-
creased all-cause mortality [25]. Recently it was shown
that both low MBL levels and low expressing MBL2 geno-
types were associated with graft loss after kidney trans-
plantation in patients without prior detectable HLA
immunization [26]. This and other observations support
the notion that MBL may be important to maintain car-
diovascular homeostasis, particularly during chronic in-
flammation, including the importance of lectins in the
pathogenesis of several inflammatory diseases [27]. Endo-
thelial function has previously been found to be impaired
in both uraemia [9] and in diabetes [28] and may reflect
presence of vascular disease or early vascular damage, but
in the present study we found no difference in FMD or
NID between the two groups. Our cohorts had no signs ofTable 3 Genetic MBL2-variants stratified according to
MBL levels
MBL2-variant MBL < 722 ug/L MBL > 722 ug/L
A/A 2 44
A/O 41 5
O/O 6 0infection and only few diabetics in each group, partly
explaining the missing difference between groups in FMD
and NID. The overall tendency to infection is however in-
creased in uraemic patients, and aggravated by MBL defi-
ciency, with a high burden of dialysis-related infections
and risk of bacteraemia during the dialysis sessions poten-
tially leading to damage of the elastic tissue of the arteries
and to an increased arterial stiffness thereby increasing
the risk of arteriosclerotic vascular disease.Figure 1 MBL levels according to MBL2 genetic variants. The figure
illustrates median, interquartile range and minimum/maximum MBL
levels stratified by OO/AO/AA MBL2 genetic variants.
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AA expression genotype with the highest level of MBL
would in theory have the best protection against infections,
and thereby the lowest PWV and the highest FMD. This is
in accordance with our findings with regard to PWV
whereas no effect of MBL on FMD was demonstrated.
However, PWV and FMD are not necessarily part in a uni-
fied pathophysiological vascular process in uraemia and
may be differently influenced by different cardiovascular
risk factors such as MBL.
The MBL-genotype A/A clearly was most represented
in the high MBL-group in our cohort, potentially indicat-
ing a genetic element in the susceptibility to arterial dam-
age in uraemic patients, although the relative few patients
with the OO expression genotype limited the statistical
power to detect difference between the groups.
Conclusions
We demonstrated that high levels of MBL are associated
with lower PWV and an increased use of antihypertensive
drugs in a cohort of patients with ESRD awaiting kidney
transplantation suggesting a beneficial role of high levels
of MBL on arterial stiffness in uraemia. We hypothesize
that this association will result in a decreased cardiovascu-
lar and infection related mortality in patients with high
baseline MBL levels and a follow up study is planned to
address this hypothesis. The strengths of the study were a
carefully examined and characterized cohort, with solid
glucose and arterial measurements. Estimation of insulin
resistance and validated MBL measurements and deter-
mination of genetic MBL2 variants and statistical analysis
completed the study. Limitations were the cross sectional
design, relatively few patients and lack of follow up data.
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